Enzon Pharmaceuticals Files 8-K: Material Agreement
Ticker: ENZN · Form: 8-K · Filed: Jun 23, 2025 · CIK: 727510
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Enzon Pharma signed a big deal on 6/20/25. 8-K filed.
AI Summary
Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement on June 20, 2025. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates a significant new agreement for Enzon Pharmaceuticals, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood, requiring further analysis.
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Registrant
- June 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 20 Commerce Drive (address) — Business and mailing address
FAQ
What is the nature of the Material Definitive Agreement entered into by Enzon Pharmaceuticals, Inc. on June 20, 2025?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on June 20, 2025.
What other information is included in this 8-K filing besides the material agreement?
This 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
When is Enzon Pharmaceuticals, Inc.'s fiscal year end?
Enzon Pharmaceuticals, Inc.'s fiscal year ends on December 31.
Where is Enzon Pharmaceuticals, Inc. incorporated?
Enzon Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Enzon Pharmaceuticals, Inc.?
The business address of Enzon Pharmaceuticals, Inc. is 20 Commerce Drive, Suite 135, Cranford, NJ 07016.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding ENZON PHARMACEUTICALS, INC. (ENZN).